The trial is funded by the Biomedical Advanced Development Authority (BARDA) and the National Institute of Allergy and Infectious Diseases (NIAID).
Up to 30,000 adults aged 18 years or older will be enrolled to assess the safety and immunogenicity of AZD1222, which was co-invented by the University of Oxford and Vaccitech.
For more information, read the full article from Drug Topics.
